Anti-ROR1/B7H3 ADC

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameAnti-ROR1/B7H3 ADC
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD276Anti-Inactive tyrosine-protein kinase transmembrane receptor ROR1
TargetsCD276 antigenInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLegochem Biosciences IncAbl Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio IncLegochem Biosciences Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A